Phase II trial of docetaxel in advanced or metastatic endometrial cancer: A Japanese Cooperative Study

British Journal of Cancer

Volumn 93, Issue 9, 2005, Pages 999-1004

  Katsumata, N ^a   Noda, K ^b   Nozawa, S ^c   Kitagawa, R ^a   Nishimura, R ^d   Yamaguchi, S ^d   Aoki, D ^c   Susumu, N ^c   Kuramoto, H ^e   Jobo, T ^e   Ueki, K ^f   Ueki, M ^f   Kohno, I ^g   Fujiwara, K ^g   Sohda, Y ^h   Eguchi, F ^h  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^e KITASATO UNIVERSITY   (Japan)

^f OSAKA MEDICAL COLLEGE   (Japan)

^g KAWASAKI MEDICAL SCHOOL   (Japan)

^h ASO IIZUKA HOSPITAL   (Japan)

Author keywords

Docetaxel; Endometrial cancer; Phase II

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DOCETAXEL;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EDEMA; ENDOMETRIUM CARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOKALEMIA; INJECTION SITE REACTION; LYMPHOCYTOPENIA; METASTASIS; MOTOR NEUROPATHY; MYCOBACTERIOSIS; NAIL DISEASE; NAUSEA; NEUTROPENIA; NEUTROPHIL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; STOMATITIS; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADENOCARCINOMA, PAPILLARY; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; JAPAN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; SURVIVAL RATE; TAXOIDS;

EID: 27644465342     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602817     Document Type: Article

References (31)

1. Asbury RF, Blessing JA, McGuire WP, Hanjani P, Mortel R (1990) Aminothiadiazole (NSC 4728) in patients with advanced carcinoma of the endometrium. A phase II study of the Gynecologic Oncology group. Am J Clin Oncol 13: 39-41
2. Ball HG, Blessing JA, Lentz SS, Mutch DG (1996) A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 62: 278-281
3. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F (1995) Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs 6: 339-355, 363-368
4. Deppe G, Cohen CJ, Bruckner HW (1980) Treatment of advanced endometrial adenocarcinoma with cis-dichlorodiammine platinum (II) after intensive prior therapy. Gynecol Oncol 10: 51-54
5. Dimopoulos MA, Papadimitriou CA, Georgoulias V, Moulopoulos LA, Aravantinos G, Gika D, Karpathios S, Stamatelopoulos S (2000) Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecol Oncol 78: 52-57
6. Fleming GF, Brunetto VL, Bentley R, Rader J, Clarke-Pearson D, Asorosky J, Eaton L, Gallion H, Gibbons WE (2000) Randomized trial of doxorubicin plus cisplatin vs doxorubicin plus paclitaxel plus granulocyte colony-stimulating factor in patients with advanced or recurrent endometrial cancer: a report on Gynecologic Oncology Group protocol. Proc Am Soc Clin Oncol 19: 1498 (abstract)
7. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT (2004) Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22: 2159-2166
8. Homesley HD, Blessing JA, Conroy J, Hatch K, DiSaia PJ, Twiggs LB (1986) ICRF-159 (razoxane) in patients with advanced adenocarcinoma of the endometrium. A Gynecologic Oncology Group Study. Am J Clin Oncol 9: 15-17
9. Hoskins PJ, Swenerton KD, Pike JA, Wong F, Lim P, Acquino-Parsons C, Lee N (2001) Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 19: 4048-4053
10. Hsu Y, Sood AK, Sorosky JI (2004) Docetaxel vs paclitaxel for adjuvant treatment of ovarian cancer. Case - control analysis of toxicity. Am J Clin Oncol 27: 14-18
11. Lincoln S, Blessing JA, Lee RB, Rocereto TF (2003) Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 88: 277-281
12. Lissoni A, Zanetta G, Losa G, Gabriele A, Parma G, Mangioni C (1996) Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol 7: 861-863
13. Moore TD, Phillips PH, Nerenstone SR, Cheson BD (1991) Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. J Clin Oncol 9: 1071-1088
14. Muggia FM, Blessing JA, Sorosky J, Reid GC (2002) Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol 20: 2360-2364
15. Muss HB, Blessing JA, DuBeshter B (1993) Echinomycin in recurrent and metastatic endometrial carcinoma. A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 16: 492-493
16. Muss HB, Bundy BN, Adcock L (1991) Teniposide (VM-26) in patients with advanced endometrial carcinoma. A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 14: 36-37
17. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M (1997) Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 15: 3149-3155
18. Rose PG, Blessing JA, Lewandowski GS, Creasman WT, Webster KD (1996) A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 63: 101-104
19. Scudder SA, Liu PY, Wilczynski SP, Smith HO, Jiang C, Hallum III AV, Smith GB, Hannigan EV, Markman M, Alberts DS (2005) Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of Southwest Oncology Group. Gynecol Oncol 96: 610-615
20. Slayton RE, Blessing JA, Delgado G (1982) Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Cancer Treat Rep 66: 1669-1671
21. Slayton RE, Blessing JA, DiSaia PJ, Phillips G (1988) A phase II clinical trial of diaziquone in the treatment of patients with recurrent endometrial carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol 11: 612-613
22. Stehman FB, Blessing JA, Delgado G, Louka M (1983) Phase II evaluation of dianhydrogalactitol in the treatment of advanced endometrial adenocarcinoma: a Gynecologic Oncology Group Study. Cancer Treat Rep 67: 737-738
23. Sutton GP, Blessing JA, Homesley HD, McGuire WP, Adcock L (1994) Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study. Cancer 73: 1453-1455
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
25. Thigpen JT, Blessing JA, Homesley H, Creasman WT, Sutton G (1989) Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 33: 68-70
26. Thigpen JT, Blessing JA, Homesley HD, Petty W (1986) Phase II trial of piperazinedione in the treatment of advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group Study. Am J Clin Oncol 9: 21-23
27. Thigpen JT, Blessing JA, Lagasse LD, DiSaia PJ, Homesley HD (1984a) Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol 7: 253-256
28. Thigpen JT, Blessing JA, Lagasse LD, DiSaia PJ, Homesley HD (1984b) Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol 7: 253-256
29. Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, Liao S (2004) Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22: 3902-3908
30. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W, Curran W (2000) Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47: 13-47
31. van Wijk FH, Lhomme C, Bolis G, Scotto di Palumbo V, Tumolo S, Nooij M, de Oliveira CF, Vermorken JB (2003) Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group. Eur J Cancer 39: 78-85